Caribou Biosciences, Inc.
Clinical trials sponsored by Caribou Biosciences, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing CRISPR-based cell therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Gene-Edited cell therapy for lupus trial pulled before it started
Disease control CancelledThis early-stage study aimed to test a single infusion of CB-010, a CRISPR-edited CAR-T cell therapy made from donor cells, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are availa…
Phase 1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:51 UTC
-
15-Year safety check for caribou cell therapy patients
Knowledge-focused By invitation onlyThis study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…
Sponsor: Caribou Biosciences, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC